Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity for pharmaceutical manufacturers in China. The drug-treatment rate for breast cancer has increased over the last few years in China owing to the launch of novel, premium-priced, targeted therapies (e.g., pertuzumab [Roche’s Perjeta]) and the inclusion of these agents in the National Reimbursement Drug List (NRDL). With a strong late-phase pipeline, we expect additional new agents to be launched, leading to further market growth during the forecast period. Additionally, with the ongoing reforms in the regulatory and access and reimbursement landscape of China, multinational companies are likely to be increasingly encouraged to enter the breast cancer therapy market.
- How large is China’s drug-treatable breast cancer population, and how will the drug-treatment rate change during the forecast period?
- Which are the most commercially relevant drugs in China’s breast cancer market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the key market access considerations for key therapies in the breast cancer pipeline in China? What sales could they secure in breast cancer? What are interviewed experts’ opinions of the key emerging therapies?
- What are the key drivers and constraints in the Chinese breast cancer market, and how will the market evolve over the forecast period?
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 75 surveys with oncologists supported by survey data collected for this and other DRG research epidemiology. Includes the diagnosed incidence of breast cancer in urban versus rural China and clinically relevant and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient shares of key breast cancer regimens through 2029, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR:10+ drugs; Phase II: 10+ drugs; coverage of select preclinical and Phase I products
China in-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.